Designer broad-spectrum polyimidazolium antibiotics

Zhong, WB; Shi, ZY; Mahadevegowda, SH; Liu, B; Zhang, KX; Koh, CH; Ruan, L; Chen, YH; Zeden, MS; Pee, CJE; Marimuthu, K; De, PP; Ng, OT; Zhu, YB; Chi, YR; Hammond, PT; Yang, L; Gan, YH; Pethe, K; Greenberg, EP; Grundling, A; Chan-Park, MB

Chan-Park, MB (corresponding author), Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637459, Singapore.; Chan-Park, MB (corresponding author), Nanyang Technol Univ, Ctr Antimicrobial Bioengn, Singapore 637459, Singapore.; Grundling, A (corresponding author), Imperial Coll London, Sect Mol Microbiol, London SW7 2AZ, England.; Grundling, A (corresponding author), Imperial Coll London, Med Res Council, Ctr Mol Bacteriol & Infect, London SW7 2AZ, England.; Chan-Park, MB (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 636921, Singapore.; Greenberg, EP (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020; 117 (49): 31376

Abstract

For a myriad of different reasons most antimicrobial peptides (AMPs) have failed to reach clinical application. Different AMPs have different shortcom......

Full Text Link